Petros developing AI tech for Phase 2 equivalent study for STENDRA

Petros Pharmaceuticals announces the development of a technological component of its self-selection study utilizing machine learning/artificial intelligence, which the Company plans to integrate into its self-selection studies for its erectile dysfunction drug STENDRA. The development of the technology and study design will continue to follow direct U.S. Food and Drug Administration recommendations as well as published proposed guidelines currently being finalized by the Agency.